Changes in bone mineral content following hormone treatment for endometriosis

• Published in: International journal of gynaecology and obstetrics Vol. 50; no. S1; pp. S17 - S22
• Main Author: Fukushima, M.
• Format: Journal Article Conference Proceeding
• Language: English
• Published: Shannon Elsevier Ireland Ltd 01.09.1995; Elsevier Science
• Subjects: Adult; Alkaline Phosphatase - blood; Biological and medical sciences; Bone Density - drug effects; Bone Density - physiology; Buserelin - administration & dosage; Buserelin - pharmacology; Creatinine - urine; Danazol; Danazol - administration & dosage; Danazol - pharmacology; Endometriosis - blood; Endometriosis - drug therapy; Endometriosis - physiopathology; Estradiol - blood; Female; Female genital diseases; Gonadotropin-releasing hormone agonist; Gynecology. Andrology. Obstetrics; Hormone therapy; Humans; Hydroxyproline - urine; Medical sciences; Middle Aged; Non tumoral diseases; Osteocalcin - blood; Osteoporosis; Single-Blind Method; Osteoporosis; Hormone therapy; Gonadotropin-releasing hormone agonist; Danazol
• ISSN: 0020-7292; 1879-3479
• DOI: 10.1016/0020-7292(95)02510-J

The effects of danazol and buserelin on the bone mineral content (BMC) of 19 Japanese women with endometriosis were studied. Subjects received 24-week courses of oral danazol (400 mg/day) or intranasal buserelin (900 μg/day). Trabecular BMC of the 3rd lumbar vertebra (L 3) was monitored by computerized tomography scans pretreatment, at the end of treatment and 6 months post-treatment. In the buserelin group there was a significant decrease in BMC (10–25.4%, P < 0.01) which was not fully reversed 6 months after therapy, and increased parameters of bone resorption. In the danazol group, there was a slight gain in BMC despite a decrease in serum estrogen. Danazol and buserelin have similar success in the treatment of endometriosis, but the decrease in BMC at L 3 suggests that cumulative bone loss may follow repeated buserelin therapy.